Salarius Pharmaceuticals, Inc.
General ticker "SLRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.6M (TTM average)
Salarius Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -23.1%.
Estimated limits based on current volatility of 3.4%: low 0.87$, high 0.93$
Factors to consider:
- Total employees count: 12 as of 2022
- Top business risk factors: Inability to raise capital, Reliance on single technology, Third-party risks, Labor/talent shortage/retention, Intellectual property risks
- Current price 90.0% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [8.73$, 33.09$]
- 2025-12-31 to 2026-12-31 estimated range: [3.84$, 15.52$]
Financial Metrics affecting the SLRX estimates:
- Negative: with PPE of -0.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -302.35 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Negative: -0.75 < Inventory ratio change, % of 0
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Negative: 41.86 < Shareholder equity ratio, % of 50.01 <= 63.39
- Negative: negative Industry operating income (median)
Short-term SLRX quotes
Long-term SLRX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $31.84MM | $12.89MM | $5.73MM |
| Operating Income | $-31.84MM | $-12.89MM | $-5.73MM |
| Non-Operating Income | $0.23MM | $0.35MM | $0.16MM |
| R&D Expense | $15.84MM | $7.17MM | $0.77MM |
| Income(Loss) | $-31.61MM | $-12.54MM | $-5.58MM |
| Profit(Loss)* | $-31.61MM | $-12.54MM | $-5.58MM |
| Stockholders Equity | $10.38MM | $5.29MM | $1.51MM |
| Assets | $14.65MM | $6.59MM | $3.02MM |
| Operating Cash Flow | $-17.60MM | $-12.85MM | $-4.53MM |
| Capital expenditure | $1.50MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-1.50MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $1.99MM | $6.64MM | $1.06MM |
| Earnings Per Share** | $-222.06 | $-57.34 | $-86.49 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.